tbuckley/cabot-search huggingface dataset:
BAP1 Loss Results in EZH2-Dependent Transformation in Myelodysplastic Syndromes
Authors: Lindsay M LaFave, Wendy Béguelin, Richard Koche, Matt Teater, Efthymia Papalexi, Barbara Spitzer, Sarah Knutson, John Campbell, Heike Keilhack, Paul M Thomas, Neil L Kelleher, Omar Abdel-Wahab, Ari M. Melnick, Scott A. Armstrong, Ross L. Levine
Journal: Blood (2015)
Loss of p53 Is a Marker of Progression in Plasma Cell Neoplasias and Is a Negative Prognostic Factor in Relapsed Disease.
Authors: Soledad Molnar, Victor J Jimenez Zepeda, Scott Van Wier, Esteban Braggio, Jonathan Keats, Michael Kuehl, Tammy Price-Troska, Greg Ahmann, Rachel Rempel, Kim Henderson, S. Vincent Rajkumar, Philip. R Greipp, Daniel Auclair, John Carpten, Angela Baker, Keith Stewart, P. Leif Bergsagel, Wee Joo Chng, Rafael Fonseca
Journal: Blood (2008)
Transformation of E2A-Deficient Pluripotent Progenitors by BCR-ABL Generates Imatinib-Resistant Leukemic Stem Cells.
Authors: Yosuke Minami, Scott A. Stuart, Tomokatsu Ikawa, Akihiro Abe, Tomoki Naoe, Catriona H.M. Jamieson, Jean Y.J. Wang
Journal: Blood (2008)
Predictors and outcomes for late recurrence of renal cell carcinoma.
Authors: S. P. Kim, C. J. Weight, B. C. Leibovich, R. H. Thompson, C. M. Lohse, S. A. Boorjian
Journal: Journal of Clinical Oncology (2011)

348 Background: While the initial natural history after surgical resection for localized renal cell carcinoma (RCC) has been well-characterized, recurrence patterns for patients who experience late recurrence of disease continue to be defined. Here, we evaluated the clinical characteristics and survival of patients who experienced disease recurrence &gt; 5 years following nephrectomy. Methods: We identified 1,454 patients who were treated with radical nephrectomy (RN) or nephron-sparing surgery (NSS) for unilateral, sporadic pT1-4NxM0 RCC between 1970-2000 and who had remained free of disease for 5 years after surgery. Late (&gt; 5 years) recurrence was then recorded and was classified as renal (ipsilateral/contralateral kidney) recurrence and distant (all other sites) recurrence. The incidence of late recurrence was estimated using the Kaplan Meier method, and clinicopathological variables subsequent disease relapse were analyzed using Cox proportional hazard regression models. Results: Median follow-up after nephrectomy in the cohort here was 13.9 years (range 5.1-38.9). In total, 63 patients experience a late recurrence in the ipsilateral/contralateral kidney, at a median of 9.3 years (range 5.1-25.3) after surgery. 172 (11.8%) patients developed late distant metastases, at a median of 9.6 years (range: 5.1-26.6). Estimated recurrence-free survival at 10 and 15 years following nephrectomy was 97.3% and 95.2% for renal recurrence and 93.1% and 85.9% for distant recurrence, respectively. Increased tumor size (HR 1.1; p&lt;0.001) was associated with a higher rate of late renal recurrence, while increased tumor size (HR 1.1; p=0.018), clear cell or collecting duct histology (HR 3.7; p&lt;0.001), and tumor stage pT1b (HR 2.8; p&lt;0.001), pT2a (HR 4.5; p&lt;0.001), pT2b (HR 3.4; p=0.007), and pT3/4 (HR 5.1; p&lt;0.001) were predictive of the development of late distant metastasis. Conclusions: Patients undergoing surgery for localized RCC remain at life-long risk of disease recurrence. Approximately 5% experience renal recurrence and 15% demonstrate distant relapse, during the ensuing 10 years. Continued investigation to identify potential site-specific predictors of late recurrence is necessary to guide postoperative surveillance regimens. No significant financial relationships to disclose.
Prediction of the nonsentinel node metastasis in patients who received neoadjuvant chemotherapy for clinically axillary lymph node metastasis.
Authors: S. Lee, S. Y. Jung, S. W. Kim, H. S. Kang, I. H. Park, K. S. Lee, J. Ro, K. Ko, Y. Kwon, K. H. Shin, S. Kim
Journal: Journal of Clinical Oncology (2011)

1111 Background: The accuracy of the nomogram about non-sentinel lymph node metastasis (NSLNM) after neoadjuvant chemotherapy (NCT) in breast cancer patients is unclear. The aim of this study was to evaluate the accuracy of the nomogram in patients with clinically axillary lymph node metastasis who received NCT. Methods: Between 2002 and 2008, patients with clinically axillary lymph node metastasis (n=178) who received NCT at National Cancer Center were studied retrospectively. At surgery, all patients showed positive sentinel lymph node metastasis and received complete axillary lymph node dissection. Four nomograms developed by Memorial Sloan-Kettering Cancer Center (MSKCC), Tenon Hospital, Seoul National University Hospital (SNUH), Louisville Breast Sentinel Lymph node Study were used to calculate the probability of NSLNM by using tumor size before NCT and after NCT for the same patients. We calculated the area under the receiver operating characteristic curve to evaluate the discrimination of the nomograms. Results: The median patients’ age was 44.9 years (range, 24-68 years). All patients presented clinically axillary lymph node metastasis before NCT and had positive sentinel lymph node metastasis at operation. All nomograms were reliably predictive for NSLNM by pathologic tumor size after NCT. Among them, the Tenon nomogram by pathologic tumor size after NCT was more predictive (area under the receiver operating characteristic curve, AUC, of 0.680). When the primary tumor size before NCT was used, the MSKCC, the SNUH and the Louisville nomograms were not predictive. But the Tenon nomogram was also predictive by primary tumor size before NCT (area under the receiver operating characteristic curve, AUC, of 0.615). Conclusions: The nomograms developed by MSKCC, Tenon Hospital, SNUH, Louisville Breast Sentinel Lymph Node Study were all reliably predictive for NSLNM by pathologic tumor size after NCT in the patients with clinically axillary lymph node metastasis. The additional large prospective studies are needed to determine predicted probability in NCT patients with clinically axillary lymph node metastasis.
Extrinsic Factors in the In Vivo Macroenvironment Generate Phenotypic Resistance to BTK/Bcl-2 Targeted Therapies in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
Authors: Kallesh D. Jayappa, Craig A. Portell, Vicki L Gordon, Brian J Capaldo, Stefan Bekiranov, Julia D Wulfkuhle, Rosa I Gallagher, Emanuel F. Petricoin, Timothy P. Bender, Michael E. Williams, Michael J. Weber
Journal: Blood (2016)
Efficacy of Oral Risperidone, Haloperidol, or Placebo for Symptoms of Delirium Among Patients in Palliative Care
Authors: Meera R. Agar, Peter G. Lawlor, Stephen Quinn, Brian Draper, Gideon A. Caplan, Debra Rowett, Christine Sanderson, Janet Hardy, Brian Le, Simon Eckermann, Nicola McCaffrey, Linda Devilee, Belinda Fazekas, Mark Hill, David C Currow
Journal: JAMA Internal Medicine (2016)

Antipsychotics are widely used for distressing symptoms of delirium, but efficacy has not been established in placebo-controlled trials in palliative care.To determine efficacy of risperidone or haloperidol relative to placebo in relieving target symptoms of delirium associated with distress among patients receiving palliative care.A double-blind, parallel-arm, dose-titrated randomized clinical trial was conducted at 11 Australian inpatient hospice or hospital palliative care services between August 13, 2008, and April 2, 2014, among participants with life-limiting illness, delirium, and a delirium symptoms score (sum of Nursing Delirium Screening Scale behavioral, communication, and perceptual items) of 1 or more.Age-adjusted titrated doses of oral risperidone, haloperidol, or placebo solution were administered every 12 hours for 72 hours, based on symptoms of delirium. Patients also received supportive care, individualized treatment of delirium precipitants, and subcutaneous midazolam hydrochloride as required for severe distress or safety.Improvement in mean group difference of delirium symptom score (severity range, 0-6) between baseline and day 3. Five a priori secondary outcomes: delirium severity, midazolam use, extrapyramidal effects, sedation, and survival.Two hundred forty-seven participants (mean [SD] age, 74.9 [9.8] years; 85 women [34.4%]; 218 with cancer [88.3%]) were included in intention-to-treat analysis (82 receiving risperidone, 81 receiving haloperidol, and 84 receiving placebo). In the primary intention-to-treat analysis, participants in the risperidone arm had delirium symptom scores that were significantly higher than those among participants in the placebo arm (on average 0.48 Units higher; 95% CI, 0.09-0.86; P = .02) at study end. Similarly, for those in the haloperidol arm, delirium symptom scores were on average 0.24 Units higher (95% CI, 0.06-0.42; P = .009) than in the placebo arm. Compared with placebo, patients in both active arms had more extrapyramidal effects (risperidone, 0.73; 95% CI, 0.09-1.37; P = .03; and haloperidol, 0.79; 95% CI, 0.17-1.41; P = .01). Participants in the placebo group had better overall survival than those receiving haloperidol (hazard ratio, 1.73; 95% CI, 1.20-2.50; P = .003), but this was not significant for placebo vs risperidone (hazard ratio, 1.29; 95% CI, 0.91-1.84; P = .14).In patients receiving palliative care, individualized management of delirium precipitants and supportive strategies result in lower scores and shorter duration of target distressing delirium symptoms than when risperidone or haloperidol are added.anzctr.org.au Identifier: ACTRN12607000562471.
Long-term cardiopulmonary mortality after radiation for locally advanced esophageal cancer.
Authors: Abigail Berman Milby, Andrzej Pawel Wojcieszynski, Smith Apisarnthanarax, James M. Metz, John Peter Plastaras
Journal: Journal of Clinical Oncology (2012)

99 Background: Radiation (RT) is considered an integral component of trimodality therapy for locally-advanced esophageal carcinoma to improve locoregional control and potentially survival. However, the long-term risk of cardiopulmonary mortality (CPM) is not well-understood in this population. Methods: Patients age 20-85 with esophageal carcinoma with T3, T4 or node positive (N+) disease who underwent esophagectomy were identified within 17 Surveillance, Epidemiology, and End Results registries from 1988-2006. Patients with metastatic disease or &lt;6 mo follow up were excluded. CPM was calculated for patients receiving vs not receiving RT and compared by the Kaplan-Meier method. The log-rank test was used for univariate associations and Cox proportional hazards model was used for multivariate analysis (MVA). Results: A total of 4,079 patients met the defined selection criteria of whom 2,408 were treated with RT, and 1,671 were not. Median age was 62.2 yrs (22-84) and follow-up was 22 mos (6-248). There was no significant difference in CPM in patients who received RT versus those who did not (p=0.8). At 10 yr, the majority of deaths were from esophageal cancer (73 with vs 78% without RT) compared to CPM (13.7 with vs 11.6% without RT). On univariate analysis ( table ), age &lt;60, diagnosis era, and histology were significant independent predictors of CPM. On MVA, age &lt;60 (HR 0.36) and diagnosis era (0.63 for 1994-2000 and 0.55 for 2000-2006) remained statistically significant for CPM. Conclusions: RT for esophageal cancer is not associated with an increased long-term risk of CPM in the overall population. Older age and earlier diagnosis era predict for CPM. Although survival in esophageal cancer is dominated by cancer deaths, advances in RT are still needed to prevent excess treatment-related mortality. [Table: see text]
Haploidentical Transplantation Outcome Is Not Inferior to Standard Matched Related and Unrelated Donor Transplantation: An Intention-to-Treat Analysis of 241 Patients with Acute Myeloid Leukemia
Authors: Maria Teresa Lupo-Stanghellini, Matteo Carrabba, Elisa Sala, Sara Mastaglio, Magda Marcatti, Michela Tassara, Andrea Assanelli, Carlo Messina, Katharina Fleischhauer, Sarah Marktel, Elena Guggiari, Francesca Lunghi, Salvatore Gattillo, Laura Bellio, Milena Coppola, Chiara Bonini, Claudio Bordignon, Consuelo Corti, Jacopo Peccatori, Massimo Bernardi, Fabio Ciceri
Journal: Blood (2012)
Paraneoplastic Syndrome With Anti-NMDAR Encephalitis Associated With Ovarian Teratomas
Authors: Puskar Pattanayak, Lilja B. Solnes
Journal: Clinical Nuclear Medicine (2016)

We report on a 33-year-old woman who had a paraneoplastic syndrome with anti-N-methyl-d-aspartate receptor encephalitis, associated with ovarian teratomas. She presented with acute onset seizures, grandiosity, elevated mood, disorganized thoughts, and paranoia. Cerebral spinal fluid analysis revealed anti-N-methyl-d-aspartate receptor antibodies. A PET/CT was requested, which identified a possible fat and calcification containing right adnexal lesion on the noncontrast CT portion, which was suspicious for a teratoma. Subsequent ultrasound revealed bilateral masses consistent with teratomas. She underwent laparoscopic removal of these masses, which were both confirmed to be mature cystic teratomas on pathology. After surgery, her symptoms progressively improved.
Improved Myeloma Targeting by Combination of the Human Anti-CD38 Antibody Daratumumab with Lenalidomide and Bortezomib
Authors: Michael S. van der Veer, Michel de Weers, Berris van Kessel, Joost M Bakker, Shulamiet Wittebol, Paul W.H.I. Parren, Henk M Lokhorst, Tuna Mutis
Journal: Blood (2010)
Patterns of utilization of urine-based markers in non-muscle-invasive bladder cancer: Results from the BCAN/SUO/AUA/LUGPA electronic survey.
Authors: A. Smith, M. E. Nielsen, J. Ferguson, A. Manvar, R. Pruthi, E. Wallen, Y. Lotan
Journal: Journal of Clinical Oncology (2011)

261 Background: In addition to cytologic evaluation, there are currently four urine-based tests approved by the FDA for bladder cancer detection. At this point, the Guidelines panels from the AUA and EAU do not make specific recommendations about the ideal role of these tests. Furthermore, there is a paucity of data on current patterns of care in this area of practice. Methods: An electronic survey was developed by the Bladder Cancer Advocacy Network (BCAN) to elicit self-reported practices of the use of cytology and urine-based markers in the settings of general use, surveillance, and assessment of response after intravesical therapy for patients with NMIBC. The survey was circulated to urologists via the AUA, SUO and LUGPA distribution lists. 512 respondents completed the survey. Results: Among all respondents, 93% report sending cytology routinely (25% via barbotage) in general use. In contrast, 37% report using NMP22 in this setting, 54% report using FISH, and 32% (45% of SUO respondents vs. 31% of AUA respondents, p=0.04) responded that there is “no role for urine-based markers in this setting.” Similar proportions were reported in the specific settings of routine surveillance and post-BCG assessment. When presented with the vignette of a positive marker test and negative cytology and cystoscopy, 36% chose to proceed to the OR for biopsy, 37% chose to repeat cystoscopy and cytology in 3 months, 21% chose “no role for markers in this setting” and 13% chose “other.” Conclusions: In the absence of more specific guidance, the results of this survey suggest considerable variation in the use and interpretation of urine-based markers in NMIBC. FISH is the marker reported to be used most commonly in multiple settings, however 31-45% of respondents report “no role” for any of the tests in their practice. Greater than one out of three respondents reported taking patients for biopsy under anesthesia in the setting of an isolated positive marker. These preliminary data underscore the need for prospective studies to validate the optimal role of urine-based markers in the setting of NMIBC. No significant financial relationships to disclose.
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma
Authors: Douglas G. McNeel, Neil H. Bander, Tomasz M. Beer, Charles G. Drake, Lawrence Fong, Stacey Harrelson, Philip W. Kantoff, Ravi A. Madan, William K. Oh, David J. Peace, Daniel P. Petrylak, Hank Porterfield, Oliver Sartor, Neal D. Shore, Susan F. Slovin, Mark N. Stein, Johannes Vieweg, James L. Gulley
Journal: Journal for ImmunoTherapy of Cancer (2016)

Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer death among men in the United States. In recent years, several new agents, including cancer immunotherapies, have been approved or are currently being investigated in late-stage clinical trials for the management of advanced prostate cancer. Therefore, the Society for Immunotherapy of Cancer (SITC) convened a multidisciplinary panel, including physicians, nurses, and patient advocates, to develop consensus recommendations for the clinical application of immunotherapy for prostate cancer patients. To do so, a systematic literature search was performed to identify high-impact papers from 2006 until 2014 and was further supplemented with literature provided by the panel. Results from the consensus panel voting and discussion as well as the literature review were used to rate supporting evidence and generate recommendations for the use of immunotherapy in prostate cancer patients. Sipuleucel-T, an autologous dendritic cell vaccine, is the first and currently only immunotherapeutic agent approved for the clinical management of metastatic castrate resistant prostate cancer (mCRPC). The consensus panel utilized this model to discuss immunotherapy in the treatment of prostate cancer, issues related to patient selection, monitoring of patients during and post treatment, and sequence/combination with other anti-cancer treatments. Potential immunotherapies emerging from late-stage clinical trials are also discussed. As immunotherapy evolves as a therapeutic option for the treatment of prostate cancer, these recommendations will be updated accordingly.
Improvement in Clinical Outcome of FLT3 Mutated AML Patients over the Last One and a Half Decade
Authors: Talha Badar, Hagop M. Kantarjian, Gautam Borthakur, Guillermo Garcia Manero, Michael Andreeff, Marina Konopleva, Tapan M. Kadia, Naval Daver, William G. Wierda, Farhad Ravandi, Jorge E. Cortes
Journal: Blood (2014)
Impact of pathologic tumor characteristics in patients with sarcomatoid renal cell carcinoma.
Authors: B. Shuch, G. Bratslavsky, J. H. Shih, D. Finley, B. Castor, W. Linehan, A. J. Pantuck, J. Said, A. S. Belldegrun
Journal: Journal of Clinical Oncology (2011)

343 Background: Patients with sarcomatoid renal cell carcinoma (sRCC) are known to have a poor prognosis and response to therapy. We sought to determine the influence of pathologic tumor characteristics on outcome in order to aid clinical management. Methods: A single center database was reviewed from 1989-2009 to identify all patients with sRCC. Clinical and staging variables were collected and pathologic information including histology, necrosis, percentage of sarcomatoid features (PSF), and microvascular invasion (MVI) was recorded. Influence of clinicopathologic variables on outcome was assessed. Results: A total of 104 patients had confirmed sRCC. The median size of tumors was 9.5 cm (range 2.5-30), 65% of patients had areas of clear cell RCC, and 69.2% had metastatic disease at presentation. The PSF did not influence tumor size, stage, necrosis, MVI, nodes, or metastasis. A total of 85 patients (81.7%) died during the follow-up period with a median survival of 5.9 months. In the overall cohort poor performance status, metastatic disease, and MVI were independent predictors of poor survival. Increased PSF was associated with worse outcome, but it failed to reach significance on multivariate analysis. In a subset analysis of those with non-metastatic disease, MVI and non-clear histology influenced prognosis, but only PSF was the only predictor of outcome. Conclusions: The PSF has limited influence on pathologic characteristics. However, increased PSF amounts may impact survival, especially in those with non-metastatic disease. The presence of MVI is an independent predictor of poor outcome while carcinoma grade and subtype have limited impact on survival. When counseling patients or designing clinical trials for these patients, PSF and MVI, not carcinoma grade or subtype should be considered. No significant financial relationships to disclose.
RECQL4 Modulates MDR1 Expression and Chemoresistance—Response
Authors: Yongliang Zhao
Journal: Cancer Research (2016)

This letter is to address the major comment raised by Dr. Paola Perego (Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy) that the decreased sensitivity to cisplatin treatment in gastric cancer cells is mainly mediated by AKT instead of MDR1 activation (1).MDR1 is shown to confer survival advantage and this function may be functionally linked to its elevation by YB1 through Akt activation. Furthermore, our study identified Akt-YB1 and MDR1 axis as a downstream target of RecQL4, and it is difficult to assess the relative importance and influence of each of these components in cisplatin resistance (2). As we have not carried out the absorption as well as efflux of cisplatin in this study, we have based our discussion on our suggestive correlation observed between RecQL4 and the Akt-YB1 and MDR1 axis rather than MDR1 alone.While I agree with the fact that cisplatin is not a substrate for P-glycoprotein, the efflux efficiency may vary for various cell types, particularly cancer cells. MDR1 inhibitor has been observed to affect the enhanced efflux by cisplatin treatment, and MDR1 expression can be augmented by cisplatin treatment (3). In addition, accumulating evidence has demonstrated the association between MDR1 activation and cisplatin resistance in a variety of cancer cells (4–6).To further address the above issue, we have examined the level of AKT activation in gastric cancer cell lines by Western blotting (data not shown). We observed that four cell lines (MGC-803, AGS, SNU-1, and NCI-N87) showed a consistency between p-AKT levels and their sensitivity to cisplatin treatment; however, inconsistency between p-AKT and sensitivity to cisplatin was also observed in other three GC cell lines. For example, SNU-16 cell line was shown to be highly resistant to cisplatin (1), but had a low level of p-AKT. In contrast, although HGC-27 and MKN45 cell lines had a high level of p-AKT, their resistant capability to cisplatin was only marginally increased in comparison with AGS and NCI-N87 cells (2). Therefore, these observations strongly support that both AKT activation and RecQL4 overexpression should exist for the eventually enhanced YB1 and MDR1 activation and cisplatin-resistant phenotype in human GC cells.See the original Letter to the Editor, p. 7290No potential conflicts of interest were disclosed.
Clinical Relevance of Soluble HLA-I as Compared to b2-MicroglobulinLevels in Non-Hodgkin’s Lymphoma and Hodgkin’s Disease.
Authors: Maher Albitar, Julie M. Vose, Marcella M. Johnson, Kim-Ann Do, Amanda Day, Iman Jilani, Hagop Kantarjian, Michael Keating, Susan M. O’Brien, Srdan Verstovsek, James O. Armitage, Francis J. Giles
Journal: Blood (2004)